Afabicin

N/A

Report date: 2025/11/02 20:00:06

QIDP

Base Information

Drug NameAfabicin

Drug Alias NameAfabicin bis(ethanolamine)(E)-(6-((N-methyl-((3-methylbenzofuran-2-yl)methyl)amino)-3-oxoprop-1-en-1-yl)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl phosphate, bis ethanolamine saltDebio 1450 bis ethanolamine saltAFN-1720AFN-17201200 +[8]

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionEnoyl-acyl-carrier protein reductase inhibitors

TargetsEnoyl-acyl-carrier protein reductase

Therapy Area/IndicationsJoint DiseasesBone Diseases, InfectiousBacterial Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUkraineSouth Africa +[5]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc Affinium Pharmaceuticals Ltd Debiopharm Group

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesDebiopharm International Sa

Active IndicationsN/A

Inactive IndicationsJoint DiseasesBone Diseases, InfectiousBacterial Infections

Other Information

ATC CodeN/A